Diagnosis of Irritable Bowel Syndrome: Role of Potential Biomarkers
Open accessThe DOI matches its Crossref record; 69 of the 71 references it cites were found in a registry or an index.
Abstract
Irritable bowel syndrome is a disorder diagnosed on symptom-based criteria without inclusion of any objective parameter measurable by known diagnostic methods. Heterogeneity of the disorder and overlapping with more serious organic diseases increase uncertainty for the physician’s work and increase the cost of confirming the diagnosis. This paper is an attempt to summarize the efforts to find adequate biomarkers for irritable bowel syndrome, which should shorten the time to diagnosis and reduce the cost. Most of the reviewed papers were observational studies from secondary care institutions. Since publication of the Rome III criteria in 2006, most recent studies use these for the recruitment of IBS patients. This is a positive step forward as future studies should use the same criteria, facilitating comparison of their results. Among the studied biomarkers, most evidence is provided for fecal calprotectin. Cutoff values for fecal calprotectin have still to be investigated prior to inclusion in the irritable bowel syndrome diagnostic algorithm.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“In contrast, patients with severe IBS symptoms in the absence of organic disease could be subjected to unnecessary repeated tests.13,51”
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Biomarkers and surrogate endpoints: Preferred definitions and conceptual framework
(2001) · Clinical Pharmacology & Therapeutics · doi:10.1067/mcp.2001.113989 · Cited by 6,762 · cited 1×
“In 2001, the term “biomarker” was defined as “a characteristic that is measured and evaluated as an indicator of normal biological processes, pathogenetic processes or pharmacologic responses to a therapeutic agent” [41].”
BackgroundCoates, M. D., Mahoney, C. R., Linden, D. R., Sampson, J. E., Chen, J., Blaszyk, H., Crowell, M. D., Sharkey, K. A., Gershon, M. D., & Mawe, G. M. (2004) · Gastroenterology · doi:10.1053/j.gastro.2004.03.013 · Cited by 765 · cited 1×
“showed that 50% of patients with IBD in long-standing remission have IBS-like symptoms [37].”
BackgroundAn Evidence-Based Position Statement on the Management of Irritable Bowel Syndrome
American College of Gastroenterology IBS Task Force (2009) · The American Journal of Gastroenterology · doi:10.1038/ajg.2008.122 · Cited by 694 · cited 1×
“Introduction Irritable bowel syndrome (IBS) is defined as a functional disorder of the lower gastrointestinal (GI) tract, which manifests as abdominal pain and/or discomfort accompanied by altered bowel function, in the absence of biochemical or structural pathology [1].”
BackgroundHigh-throughput diversity and functionality analysis of the gastrointestinal tract microbiota
Zoetendal, E. G., Rajilić-Stojanović, M., & de Vos, W. M. (2008) · Gut · doi:10.1136/gut.2007.133603 · Cited by 673 · cited 1×
“Altered fecal microbiota is described in a subset of patients with IBS compared with healthy controls [24, 25].”
BackgroundAssessment of the Neutrophil Dominating Protein Calprotectin in Feces: A Methodologic Study
RØseth, A. G., Fagerhol, M. K., Aadland, E., & Schjønsby, H. (1992) · Scandinavian Journal of Gastroenterology · doi:10.3109/00365529209011186 · Cited by 669 · cited 1×
“It is released into the intestine during colonic inflammation and is resistant to colonic degradation so it can easily be measured in stool [58].”
BackgroundDinan, T. G., Quigley, E. M. M., Ahmed, S. M. M., Scully, P., O’Brien, S., O’Mahony, L., O’Mahony, S., Shanahan, F., & Keeling, P. W. N. (2006) · Gastroenterology · doi:10.1053/j.gastro.2005.11.033 · Cited by 636 · cited 1×
“showed an increased number of IL-6 and IL-8 in IBS subgroups (diarrhea predominant, constipated, and alternators) [15].”
BackgroundCollins, S. M., & Bercik, P. (2009) · Gastroenterology · doi:10.1053/j.gastro.2009.01.075 · Cited by 612 · cited 1×
“The brain-gut axis (BGA) consists of the peripheral neuroendocrine system, central nervous system, particularly the autonomic nervous system, and the hypothalamic-pituitary-adrenal (HPA) axis [31].”
BackgroundDunlop, S. P., Jenkins, D., Neal, K. R., & Spiller, R. C. (2003) · Gastroenterology · doi:10.1053/j.gastro.2003.09.028 · Cited by 583 · cited 1×
“The authors suggest that this finding could be the result of enterochromaffin cell hyperplasia found in PI-IBS patients [54, 55].”
BackgroundTHABANE, M., KOTTACHCHI, D. T., & MARSHALL, J. K. (2007) · Alimentary Pharmacology & Therapeutics · doi:10.1111/j.1365-2036.2007.03399.x · Cited by 466
Tibble, J. A., Sigthorsson, G., Foster, R., Forgacs, I., & Bjarnason, I. (2002) · Gastroenterology · doi:10.1053/gast.2002.34755 · Cited by 441 · cited 2×
“mention that cutoff FC levels of 30mg/kg combined with Rome I criteria can serve as a clear proof of IBS with no need for further examination [61].”
BackgroundMethodBacillary dysentery as a causative factor of irritable bowel syndrome and its pathogenesis
Wang, L.-H., Fang, X.-C., & Pan, G.-Z. (2004) · Gut · doi:10.1136/gut.2003.021154 · Cited by 387 · cited 1×
“Low-grade inflammation through the presence of different immune cells such as leukocytes, lymphocytes, and mast cells in this subtype of IBS patients is mentioned in different studies [21, 22].”
BackgroundDiarrhoea-predominant IBS patients show mast cell activation and hyperplasia in the jejunum
Guilarte, M., Santos, J., de Torres, I., Alonso, C., Vicario, M., Ramos, L., Martinez, C., Casellas, F., Saperas, E., & Malagelada, J. R. (2007) · Gut · doi:10.1136/gut.2006.100594 · Cited by 385 · cited 1×
“This is why an increased number of mast cells and their supposed role in certain IBS symptoms are the most consistent finding so far [11, 16].”
BackgroundCremon, C., Gargano, L., Morselli-Labate, A. M., Santini, D., Cogliandro, R. F., De Giorgio, R., Stanghellini, V., Corinaldesi, R., & Barbara, G. (2009) · The American Journal of Gastroenterology · doi:10.1038/ajg.2008.94 · Cited by 342 · cited 2×
“The authors managed to show a statistically relevant connection between mucosal mast cell infiltration and frequency of abdominal bloating [11].”
BackgroundIrritable bowel syndrome: A microbiome-gut-brain axis disorder?
Kennedy, P. J. (2014) · World Journal of Gastroenterology · doi:10.3748/wjg.v20.i39.14105 · Cited by 331 · cited 1×
“Since it is considered that stable but diverse microbiota is beneficial to health, these changes in the composition of microbiota can result in IBS symptoms [26].”
BackgroundEarly Life Risk Factors That Contribute to Irritable Bowel Syndrome in Adults: A Systematic Review
Chitkara, D. K., van Tilburg, M. A. L., Blois-Martin, N., & Whitehead, W. E. (2008) · The American Journal of Gastroenterology · doi:10.1111/j.1572-0241.2007.01722.x · Cited by 303 · cited 1×
“” Early life trauma and chronic stress are confirmed as major risk factors for IBS; therefore the idea of measuring cortisol levels in these patients and searching for disturbances in theHPAaxis seems a logical way of proceeding with research into the origin of disorders [47, 48].”
BackgroundWaugh, N., Cummins, E., Royle, P., Kandala, N.-B., Shyangdan, D., Arasaradnam, R., Clar, C., & Johnston, R. (2013) · Health Technology Assessment · doi:10.3310/hta17550 · Cited by 286 · cited 1×
“Similarly, in a report published in 2013, fecal calprotectin is confirmed as a highly specific and sensitive biomarker for IBD and a value from 50mcg/g showed 93% sensitivity and 94% specificity in differentiating IBD from IBS [62].”
BackgroundKeohane, J., O'Mahony, C., O'Mahony, L., O'Mahony, S., Quigley, E. M., & Shanahan, F. (2010) · American Journal of Gastroenterology · doi:10.1038/ajg.2010.156 · Cited by 253
Colonic endocrine cells in inflammatory bowel disease
El‐Salhy, M., Danielsson, Å., Stenling, R., & Grimelius, L. (1997) · Journal of Internal Medicine · doi:10.1046/j.1365-2796.1997.00237.x · Cited by 235 · cited 1×
“Several studies have reported changes in the EC population and 5-HT content in inflammatory bowel disease (IBD) and in IBS [36].”
BackgroundAssociation of symptoms with gastrointestinal microbiota in irritable bowel syndrome
Malinen, E. (2010) · World Journal of Gastroenterology · doi:10.3748/wjg.v16.i36.4532 · Cited by 218 · cited 1×
“A direct link has not been found although many researches are trying to investigate the incidence of symptoms and special species of bacteria [27].”
BackgroundClarke, G., Cryan, J. F., Dinan, T. G., & Quigley, E. M. (2012) · Alimentary Pharmacology & Therapeutics · doi:10.1111/j.1365-2036.2011.04965.x · Cited by 216 · cited 1×
“Indirect evidence of the role of microbiota is based on the observed beneficial effect of probiotics on IBS symptoms [28].”
BackgroundIrritable bowel syndrome: Diagnosis and pathogenesis
El-Salhy, M. (2012) · World Journal of Gastroenterology · doi:10.3748/wjg.v18.i37.5151 · Cited by 213 · cited 1×
“Around 75% of patients are alternators, which illustrates the instability of symptoms over time in the samepatient [3].”
Carroll, I. M., Chang, Y.-H., Park, J., Sartor, R. B., & Ringel, Y. (2010) · Gut Pathogens · doi:10.1186/1757-4749-2-19 · Cited by 203 · cited 1×
“Altered fecal microbiota is described in a subset of patients with IBS compared with healthy controls [24, 25].”
BackgroundPARK, J. H., RHEE, P., KIM, H. S., LEE, J. H., KIM, Y., KIM, J. J., & RHEE, J. C. (2006) · Journal of Gastroenterology and Hepatology · doi:10.1111/j.1440-1746.2005.04143.x · Cited by 196 · cited 1×
“Mast cell infiltration is found throughout the GI tract and its role in inflammation and symptom development has attracted most attention [13].”
BackgroundSimrén, M. (2002) · The American Journal of Gastroenterology · doi:10.1016/s0002-9270(01)04037-0 · Cited by 186 · cited 2×
“The foundation for such research lies in the discovery that IBS symptoms persist in a large number of patients with CD and UC who are considered to be in remission [38].”
BackgroundIrritable bowel syndrome: Emerging paradigm in pathophysiology
Lee, Y. J. (2014) · World Journal of Gastroenterology · doi:10.3748/wjg.v20.i10.2456 · Cited by 185 · cited 1×
“Most of these are associated with inflammation, neurotransmitters, and bile acid synthesis [8].”
BackgroundGut hormones: emerging role in immune activation and inflammation
Khan, W. I., & Ghia, J. E. (2010) · Clinical and Experimental Immunology · doi:10.1111/j.1365-2249.2010.04150.x · Cited by 184
Irritable bowel syndrome: towards biomarker identification
Clarke, G., Quigley, E. M. M., Cryan, J. F., & Dinan, T. G. (2009) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2009.08.001 · Cited by 181 · cited 2×
“Thegreatest obstacles in finding biological biomarkers in IBS are heterogeneity of symptoms between patients and temporal instability of the symptoms in the same patient, also overlapping of symptoms with other functional gastrointestinal disorders (FGIDs) and more serious organic diseases, and, finally, unclear under…”
BackgroundFunctional gastrointestinal disorders and mast cells: implications for therapy
Barbara, G., Stanghellini, V., De Giorgio, R., & Corinaldesi, R. (2006) · Neurogastroenterology & Motility · doi:10.1111/j.1365-2982.2005.00685.x · Cited by 175 · cited 2×
“confirmed that acute stress induces mast cell infiltration and activation in the gut but the role of chronic stress is not yet fully investigated [12].”
BackgroundSpiller, R., & Lam, C. (2012) · Journal of Neurogastroenterology and Motility · doi:10.5056/jnm.2012.18.3.258 · Cited by 174 · cited 6×
“Thus, low-grade inflammation is considered to be the main pathophysiology of PI-IBS.”
BackgroundInfluentialLanghorst, J., Junge, A., Rueffer, A., Wehkamp, J., Foell, D., Michalsen, A., Musial, F., & Dobos, G. J. (2009) · The American Journal of Gastroenterology · doi:10.1038/ajg.2008.86 · Cited by 167 · cited 1×
“HBD-2 presents another potential biomarker whose clinical role in IBS has not been adequately investigated so far.”
BackgroundThe role of stress in symptom exacerbation among IBS patients
Blanchard, E. B., Lackner, J. M., Jaccard, J., Rowell, D., Carosella, A. M., Powell, C., Sanders, K., Krasner, S., & Kuhn, E. (2008) · Journal of Psychosomatic Research · doi:10.1016/j.jpsychores.2007.10.010 · Cited by 167 · cited 1×
“” Early life trauma and chronic stress are confirmed as major risk factors for IBS; therefore the idea of measuring cortisol levels in these patients and searching for disturbances in theHPAaxis seems a logical way of proceeding with research into the origin of disorders [47, 48].”
BackgroundSwan, C., Duroudier, N. P., Campbell, E., Zaitoun, A., Hastings, M., Dukes, G. E., Cox, J., Kelly, F. M., Wilde, J., Lennon, M. G., et al. (2013) · Gut · doi:10.1136/gutjnl-2011-301213 · Cited by 165 · cited 1×
“After completing an extensive review of the literature on pathophysiology and diagnosis of IBS we now present findings along with conclusions.”
BackgroundNew insights into the pathogenesis and pathophysiology of irritable bowel syndrome
Öhman, L., & Simrén, M. (2007) · Digestive and Liver Disease · doi:10.1016/j.dld.2006.10.014 · Cited by 155 · cited 1×
“Dysregulated BGA is a theoretical construct, which serves as an explanation for the changes in visceral hypersensitivity and gut motility, as the twomain pathophysiological causes of IBS symptoms [33].”
BackgroundSerum and Colonic Mucosal Immune Markers in Irritable Bowel Syndrome
Chang, L., Adeyemo, M., Karagiannidis, I., Videlock, E. J., Bowe, C., Shih, W., Presson, A. P., Yuan, P.-Q., Cortina, G., Gong, H., et al. (2012) · American Journal of Gastroenterology · doi:10.1038/ajg.2011.423 · Cited by 150 · cited 1×
“The need for a reliable and standard method to properly discriminate functional gastrointestinal disorders (FGIDs) has led to the development of symptom-based criteria by the Rome Foundation.”
Fichna, J., & Storr, M. A. (2012) · Frontiers in Pharmacology · doi:10.3389/fphar.2012.00127 · Cited by 140 · cited 1×
“Fichna and Storr mentioned that bidirectional communication along the neural, endocrine, and neuroimmune pathways allows signals from the GI tract to influence the brain, which in turn can exert changes in motility, secretion, and immune function [32].”
BackgroundBiomarkers in inflammatory bowel diseases: Current status and proteomics identification strategies
Bennike, T. B., Birkelund, S., Stensballe, A., & Andersen, V. (2014) · World Journal of Gastroenterology · doi:10.3748/wjg.v20.i12.3231 · Cited by 125 · cited 2×
“It focuses on cellular and secreted proteins, in terms of both their structure and the functional interaction between them [44].”
BackgroundKennedy, P. J., Cryan, J. F., Quigley, E. M. M., Dinan, T. G., & Clarke, G. (2014) · Psychological Medicine · doi:10.1017/s003329171400052x · Cited by 120 · cited 1×
“They found greater total cortisol output in response to acute stress in IBS patients and concluded that the cause lies in failure of the HPA axis to adequately shut off long after the stressor has been removed and generalized elevation in HPA axis activity [49].”
BackgroundStewart, G. T. (1950) · BMJ · doi:10.1136/bmj.1.4650.405 · Cited by 116 · cited 1×
“The term “postinfectious IBS” was used as a term for the first time in a study in the 1950s [17].”
MethodNew Insights into the Pathogenesis and Pathophysiology of Irritable Bowel Syndrome
Collins, S. M. (1992) · Springer eBooks · doi:10.1007/978-1-4615-3314-6_9 · Cited by 115
Patel, P., Bercik, P., Morgan, D. G., Bolino, C., Pintos‐Sanchez, M. I., Moayyedi, P., & Ford, A. C. (2015) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.13074 · Cited by 115 · cited 1×
“A possible reason is that several IBS symptoms can be correlated just with a too high somatization rate or some other psychosocial factors, but not to inflammatory processes [10].”
BackgroundSchwille-Kiuntke, J., Enck, P., Zendler, C., Krieg, M., Polster, A. V., Klosterhalfen, S., Autenrieth, I. B., Zipfel, S., & Frick, J.-S. (2011) · Neurogastroenterology & Motility · doi:10.1111/j.1365-2982.2011.01779.x · Cited by 110
Zhang, D., Shooshtarizadeh, P., Laventie, B., Colin, D. A., Chich, J., Vidić, J., de Barry, J., Chasserot‐Golaz, S., Delalande, F., DORSSELAER, A. V., et al. (2009) · PLoS ONE · doi:10.1371/journal.pone.0004501 · Cited by 108 · cited 1×
“The chromogranins family recently became popular in the search for the ideal biomarker for IBS since it was discovered that they can modulate intestinal inflammation and present active communication between the neuroendocrine and immune system [52].”
BackgroundCetin, Y., Kühn, M., Kulaksiz, H., Adermann, K., Bargsten, G., Grube, D., & Forssmann, W. (1994) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.91.8.2935 · Cited by 105
Utility of faecal calprotectin in inflammatory bowel disease (IBD): what cut-offs should we apply?
Dhaliwal, A., Zeino, Z., Tomkins, C., Cheung, M., Nwokolo, C., Smith, S., Harmston, C., & Arasaradnam, R. P. (2015) · Frontline Gastroenterology · doi:10.1136/flgastro-2013-100420 · Cited by 99 · cited 11×
“Similarly, in a report published in 2013, fecal calprotectin is confirmed as a highly specific and sensitive biomarker for IBD and a value from 50mcg/g showed 93% sensitivity and 94% specificity in differentiating IBD from IBS [62].”
BackgroundInfluentialÖhman, L., Isaksson, S., Lundgren, A., Simrén, M., & Sjövall, H. (2005) · Clinical Gastroenterology and Hepatology · doi:10.1016/s1542-3565(05)00410-6 · Cited by 98
Use of serum biomarkers in a diagnostic test for irritable bowel syndrome
LEMBO, A. J., NERI, B., TOLLEY, J., BARKEN, D., CARROLL, S., & PAN, H. (2009) · Alimentary Pharmacology & Therapeutics · doi:10.1111/j.1365-2036.2009.03975.x · Cited by 94 · cited 1×
“They are included in a diagnostic test shown to have 50% sensitivity and 88% specificity in differentiating IBS from non-IBS patients [51].”
BackgroundJones, M., Chey, W. D., Singh, S., Gong, H., Shringarpure, R., Hoe, N., Chuang, E., & Talley, N. J. (2014) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.12608 · Cited by 85
Chang, M.-H., Chou, J., Chen, S.-M., TSAI, M.-C., SUN, Y.-S., Lin, C.-C., & Lin, C.-P. (2014) · Molecular Medicine Reports · doi:10.3892/mmr.2014.2180 · Cited by 81 · cited 1×
“, who found significantly higher stool FC levels in IBS patients than serum CRP levels, presented an interesting finding [63].”
BackgroundUse of broad-spectrum antibiotics and the development of irritable bowel syndrome.
Villarreal, A. A., Aberger, F. J., Benrud, R., & Gundrum, J. D. (2012) · PubMed · Cited by 78
Chromogranin A as a possible tool in the diagnosis of irritable bowel syndrome
El‐Salhy, M., Lomholt-Beck, B., & Hausken, T. (2010) · Scandinavian Journal of Gastroenterology · doi:10.3109/00365521.2010.503965 · Cited by 74 · cited 2×
“Due to this finding, they propose changed density of intestinal CgA cells as a potential histopathological marker for IBS [56].”
BackgroundÖhman, L., Stridsberg, M., Isaksson, S., Jerlstad, P., & Simrén, M. (2012) · American Journal of Gastroenterology · doi:10.1038/ajg.2011.458 · Cited by 74
Alterations in the Intestinal Microbiota and Functional Bowel Symptoms
Ringel, Y., & Carroll, I. M. (2009) · Gastrointestinal Endoscopy Clinics of North America · doi:10.1016/j.giec.2008.12.004 · Cited by 73 · cited 1×
“A supposed underlying mechanism is genetic polymorphism in genes associated with immune response to pathogens and immune functioning of the individual that allows activation of a specific inflammatory response [19, 20].”
BackgroundZhang, Z.-F., Duan, Z.-J., Wang, L.-X., Yang, D., Zhao, G., & Zhang, L. (2014) · BMC Gastroenterology · doi:10.1186/1471-230x-14-23 · Cited by 71 · cited 1×
“They claim that their finding is applicable to the East Asian population and not to other populations [7].”
BackgroundPeptide Hormones as Tumor Markers in Neuroendocrine Gastrointestinal Tumors
Eriksson, B., & Oberg, K. (1991) · Acta Oncologica · doi:10.3109/02841869109092404 · Cited by 67 · cited 1×
“At present, CgA is used as a marker for neuroendocrine tumors since it represents overall activity of the endocrine system in the body [40].”
MethodThe Genetics of Irritable Bowel Syndrome
Saito, Y. A., Petersen, G. M., Locke, G. R., & Talley, N. J. (2005) · Clinical Gastroenterology and Hepatology · doi:10.1016/s1542-3565(05)00184-9 · Cited by 62
Chromogranin A Cell Density as a Diagnostic Marker for Lymphocytic Colitis
El-Salhy, M., Gundersen, D., Hatlebakk, J. G., & Hausken, T. (2012) · Digestive Diseases and Sciences · doi:10.1007/s10620-012-2249-6 · Cited by 42 · cited 1×
“Consequently, IBS becomes not only debilitating for the patient, but also a great social and economic burden [5].”
BackgroundThe role of serum chromogranin A in diarrhoea predominant irritable bowel syndrome.
Sidhu, R., McAlindon, M. E., Leeds, J. S., Skilling, J., & Sanders, D. S. (2009) · PubMed · Cited by 38
Hod, K., Dickman, R., Sperber, A., Melamed, S., Dekel, R., Ron, Y., Halpern, Z., Berliner, S., & Maharshak, N. (2011) · Neurogastroenterology & Motility · doi:10.1111/j.1365-2982.2011.01788.x · Cited by 36
Proteomic analysis of colonic mucosa in a rat model of irritable bowel syndrome
Ding, Y., Lu, B., Chen, D., Meng, L.-N., Shen, Y., & Chen, S. (2010) · PROTEOMICS · doi:10.1002/pmic.200900572 · Cited by 34 · cited 1×
“A further step should be identification of targeted proteins and observation of their expression patternwhen a noninvasive sample is used (blood, feces, and urine) [67].”
BackgroundFitzGerald, L., Kehoe, P., & Sinha, K. (2009) · Western Journal of Nursing Research · doi:10.1177/0193945909339320 · Cited by 30 · cited 1×
“The impaired tone of the HPA axis was attributed to adaptive changes in brain response to chronic stress towhich IBS patients are considered to bemore often exposed in comparison with healthy individuals [50].”
BackgroundSidhu, R., Drew, K., McAlindon, M. E., Lobo, A., & Sanders, D. S. (2009) · Inflammatory Bowel Diseases · doi:10.1002/ibd.20982 · Cited by 30 · cited 1×
“The authors suggest that this finding could be the result of enterochromaffin cell hyperplasia found in PI-IBS patients [54, 55].”
BackgroundLow-grade inflammation in the rectum of patients with sporadic irritable bowel syndrome
EL-SALHY, M., GUNDERSEN, D., HATLEBAKK, J. G., & HAUSKEN, T. (2013) · Molecular Medicine Reports · doi:10.3892/mmr.2013.1320 · Cited by 28 · cited 1×
“Low-grade inflammation through the presence of different immune cells such as leukocytes, lymphocytes, and mast cells in this subtype of IBS patients is mentioned in different studies [21, 22].”
BackgroundEditorial: Fecal Granins in IBS: Cause or Indicator of Intestinal or Colonic Irritation?
Camilleri, M. (2012) · The American Journal of Gastroenterology · doi:10.1038/ajg.2011.465 · Cited by 23 · cited 1×
“Some are discussed by Camilleri who wonders whether these elevated levels are a cause or just a consequence of GIT disturbances in IBS [57].”
BackgroundHauser, G., Tkalčić, M., Pletikosić, S., Grabar, N., & Štimac, D. (2012) · Medical Hypotheses · doi:10.1016/j.mehy.2012.03.020 · Cited by 20
Self-citationContinuing Medical Education: August 2010
(2010) · American Journal of Gastroenterology · doi:10.1038/ajg.2010.292 · Cited by 16
Searching for the Noninvasive Biomarker Holy Grail: Are Urine Proteomics the Answer?
Voss, J. G., Goo, Y. A., Cain, K. C., Woods, N. F., Jarrett, M. E., Smith, L. T., Shulman, R. J., & Heitkemper, M. M. (2011) · Biological Research For Nursing · doi:10.1177/1099800411402056 · Cited by 15 · cited 1×
“A further step should be identification of targeted proteins and observation of their expression patternwhen a noninvasive sample is used (blood, feces, and urine) [67].”
BackgroundBiological Markers of Depression
Connor, T., & Leonard, B. E. (2004) · Handbook of experimental pharmacology · doi:10.1007/978-3-642-18500-7_4 · Cited by 14
Tkalčić, M., Pletikosić, S., & Hausr, G. (2014) · Journal of Psychosomatic Research · doi:10.1016/j.jpsychores.2014.03.086 · Cited by 2 · cited 1×
“Another positive remark on FC is the opinion that FC level correlates with a reduced physical component of health related quality of life (HRQoL) [64].”
BackgroundSelf-citationA Serologic Test for Irritable Bowel Syndrome: Real Meat or Bare Bones?
Quigley, E. M. M., & Clarke, G. (2009) · Gastroenterology · doi:10.1053/j.gastro.2009.10.023 · Cited by 2 · cited 1×
“Patients are exposed to a set of invasive tests, despite the opinion that less than 5% of patients with a diagnosis of IBS based on the Rome III criteria are likely to have symptoms caused by a more serious condition [4].”
Background
Research works printed but not linked: 2
- 2012, Wisconsin Medical Journal, 111, 17
- 2009, Journal of Gastrointestinal and Liver Diseases, 18, 23
Cited by
Hustoft, T. N., Hausken, T., Ystad, S. O., Valeur, J., Brokstad, K., Hatlebakk, J. G., & Lied, G. A. (2017) · Neurogastroenterology & Motility · doi:10.1111/nmo.12969 · Cited by 218
Dumping Syndrome: A Review of the Current Concepts of Pathophysiology, Diagnosis, and Treatment
Berg, P., & McCallum, R. W. (2015) · Digestive Diseases and Sciences · doi:10.1007/s10620-015-3839-x · Cited by 162
“IBS is suggested after at least 3 months of episodic abdominal pain, provided two of the next three criteria are present: Changes in the stool consistency are present, changes in stooling frequency are present, and abdominal pain is relieved by defecation [7].”
BackgroundFaecal short-chain fatty acids - a diagnostic biomarker for irritable bowel syndrome?
Farup, P. G., Rudi, K., & Hestad, K. (2016) · BMC Gastroenterology · doi:10.1186/s12876-016-0446-z · Cited by 103
“Inflammatory Bowel Disease) and healthy volunteers, but so far none has been judged as satisfactory for the use in daily practice [5, 6].”
BackgroundMethodResultFukui, H., Nishida, A., Matsuda, S., Kira, F., Watanabe, S., Kuriyama, M., Kawakami, K., Aikawa, Y., Oda, N., Arai, K., et al. (2020) · Journal of Clinical Medicine · doi:10.3390/jcm9082403 · Cited by 88
“With regard to diagnosis, although some objective molecular markers based on blood, stool, and intestinal tissue sampling have been proposed, no valid biomarkers of IBS have yet been established [3].”
BackgroundGuagnozzi, D., Arias, Á., & Lucendo, A. J. (2016) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.13573 · Cited by 72
“IBS, and, in the absence of a colonoscopy with colonic mucosal biopsies, there is no marker for an accurate differential diagnosis between the two conditions.(14) Currently, diagnosis of IBS is symptom-based, with diagnostic criteria for each IBS-subtype as well as for functional diarrhoea.”
Background
Metadata
- Authors
- Plavšić, I., Hauser, G., Tkalčić, M., Pletikosić, S., & Salkić, N.
- Affiliations
- Klinički Bolnički Centar Rijeka (HR)
- University of Rijeka (HR)
- Department of Gastroenterology and Hepatology, University Clinical Centre Tuzla, Trnovac bb, 76000 Tuzla, Bosnia and Herzegovina
- Corresponding author
- Hauser, Goran
- Venue
- Gastroenterology Research and Practice
- Publisher
- Wiley
- Published
- 2015
- Volume
- 2015
- Pages
- 1-12
- ISSN
- 1687-6121 (ISSN-L)
- 1687-630X
- PMC
- PMC4480928
- OpenAlex
- W1586847156
- Cited by
- 37
- References
- 71
- Citations by year
- 2026: 1 · 2025: 2 · 2024: 2 · 2023: 3 · 2022: 3 · 2021: 3 · 2020: 2 · 2019: 2 · 2018: 4 · 2017: 5 · 2016: 7 · 2015: 3
- FWCI
- 1.11
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Locations
- Gastroenterology Research and Practice (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Topics
- Health Sciences › Medicine › Gastroenterology › Gastrointestinal motility and disorders
- Health Sciences › Medicine › Gastroenterology › Inflammatory Bowel Disease
- Health Sciences › Medicine › Gastroenterology › Microscopic Colitis
- Keywords
- irritable bowel syndrome, biomarkers, diagnosis, fecal calprotectin, Rome III criteria, diagnostic algorithm, diagnostic accuracy, differential diagnosis
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.